Abingdon Health Ltd, is pleased to announce the appointment of Paul Duncan to the Scientific & Medical Advisory Board.
Paul Duncan, currently the Group’s Commercial Director, will move to join the Group’s Scientific & Medical Advisory Board (“the SMA Board”). The SMA Board members will comprise of Dr Chris Hand (Chairman), Professor Donal Bradley, Professor Mark Drayson and Paul Duncan and will provide expertise in the areas considered to be important for the Abingdon Health’s future scientific development.
Prior to joining Abingdon Health, Paul was Commercial Director of The Binding Site Group. Paul spent 20 years at the Binding Site in various roles of increasing seniority, including global sales and marketing director in 2006 and CEO in 2009. Paul has a technical background in haematology and immunology.
Commenting on the announcement, Chris Yates, said:
I would like to thank Paul Duncan for his significant contribution to the development of the Group over the past two years in his role as Commercial Director. It is really pleasing for me that Paul has agreed to join the Group’s Scientific & Medical Advisory Board. Paul brings a wealth of experience within medical diagnostics to the Scientific & Medical Advisory Board and his continued contribution to the development of Abingdon Health is a great asset to the Group.”
Full press release can be viewed at https://www.abingdonhealth.com/category/company-news/